Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H1, 2018
- GDHC5086CTIDB
- Pages: 167
- June 2018
- Region : Global
- GlobalData
- Market Research Report
- Details
- Table Of Content
- Licence Rights
- Section Purchase
- Products and Companies
Details
Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H1, 2018
Summary
GlobalData's clinical trial report, Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H1, 2018" provides an overview of Relapsing Multiple Sclerosis (RMS) clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsing Multiple Sclerosis (RMS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table Of Content
Scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Relapsing Multiple Sclerosis (RMS) to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Relapsing Multiple Sclerosis (RMS) to Central Nervous System Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Relapsing Multiple Sclerosis (RMS) 31
Jun 18, 2018: TG Therapeutics Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with Multiple Sclerosis at the 4th Congress of the European Academy of Neurology 31
Jun 14, 2018: Roche announces new OCREVUS ocrelizumab data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis 31
Jun 06, 2018: Alkermes Receives USD 50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program 32
May 29, 2018: EMD Serono to Present MS Data and Debut New Patient Resources at CMSC 2018 32
May 02, 2018: Mavenclad (Cladribine Tablets) Data in Multiple Sclerosis Journal Show an Even Greater Treatment Effect in Patients with Highly Active Multiple Sclerosis 34
Apr 27, 2018: Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE (glatiramer acetate injection) 40 mg/mL 34
Apr 24, 2018: New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting 34
Apr 23, 2018: New OCREVUS (ocrelizumab) data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple Sclerosis 35
Apr 23, 2018: Relapsing MS Patients Who Switched to Aubagio (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies 36
Apr 19, 2018: Sanofi Genzyme's Multiple Sclerosis Data to Be Featured at AAN 37
Apr 19, 2018: Sanofi Genzyme Presents Investigational Data on Aubagio(teriflunomide) at AAN 37
Apr 17, 2018: Teva to Present New Data on COPAXONE at 70th Annual Meeting of the American Academy of Neurology 38
Apr 15, 2018: Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus 38
Clinical Trial Profile Snapshots 40
Appendix 165
Abbreviations 165
Definitions 165
Research Methodology 166
Secondary Research 166
About GlobalData 167
Contact Us 167
Source 167
List Of Figure
List of Figures
Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials by Region (%), 2018* 8
Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
Proportion of Relapsing Multiple Sclerosis (RMS) to Central Nervous System Clinical Trials, G7 Countries (%), 2018* 16
Relapsing Multiple Sclerosis (RMS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Relapsing Multiple Sclerosis (RMS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Relapsing Multiple Sclerosis (RMS) to Central Nervous System Clinical Trials, E7 Countries (%), 2018* 19
Relapsing Multiple Sclerosis (RMS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
Relapsing Multiple Sclerosis (RMS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22
Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23
Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Relapsing Multiple Sclerosis (RMS) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30
GlobalData Methodology 166
List Of Table
List of Tables
Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials by Region, 2018* 8
Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
Proportion of Relapsing Multiple Sclerosis (RMS) to Central Nervous System Clinical Trials, G7 Countries (%), 2018* 16
Relapsing Multiple Sclerosis (RMS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Relapsing Multiple Sclerosis (RMS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Relapsing Multiple Sclerosis (RMS) to Central Nervous System Clinical Trials, E7 Countries (%), 2018* 19
Relapsing Multiple Sclerosis (RMS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
Relapsing Multiple Sclerosis (RMS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials by Phase, 2018* 22
Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23
Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Relapsing Multiple Sclerosis (RMS) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
Products and Companies
Products
Relapsing Multiple Sclerosis (RMS) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Relapsing Multiple Sclerosis (RMS), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania
Companies
Biogen Inc
Sanofi
E. Merck KG
Novartis AG
F. Hoffmann-La Roche Ltd
Teva Pharmaceutical Industries Ltd
Celgene Corp
Pharmaceutical Product Development LLC
Perrigo Company Plc
Johnson & Johnson
Related Reports
Page 130 | 
May 2019
Page 155 | April 2019
Page 159 | March 2019
Page 222 | January 2019
Page 93 | December 2018